GSK plc ADR Stock
GSK plc ADR Stock
We can see a decrease in the price for GSK plc ADR. Compared to yesterday it has lost -€0.600 (-1.420%).
So far the community has only identified positive things for GSK plc ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of GSK plc ADR in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of GSK plc ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| GSK plc ADR | -1.420% | -4.147% | 0.971% | 27.607% | -0.478% | 26.061% | 4.000% |
| Astrazeneca ADR | -1.230% | 0.000% | 5.161% | 25.385% | 3.165% | 23.860% | 88.657% |
| Bayer AG ADR | 1.900% | 8.081% | 25.146% | 98.148% | 21.591% | -25.694% | -17.692% |
| Teva Pharmaceutical Industries Ltd ADR | -1.460% | -0.725% | 5.792% | 28.037% | 1.859% | 172.637% | 177.609% |
Comments
GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Show more
Ratings data for GSK provided by MarketBeat
GSK (NYSE:GSK) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating.
Show more
Ratings data for GSK provided by MarketBeat
GSK PLC Sponsored ADR (NYSE: GSK) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for GSK provided by MarketBeat
News
GSK Unveils Fast-Tracked IBP Transformation with OMP at Gartner Supply Chain Planning Summit
ANTWERPEN, BE / ACCESS Newswire / October 9, 2025 / OMP, a leader in supply chain planning solutions, is spotlighting at the Gartner Supply Chain Planning Summit 2025 in London how GSK is
